Dr. Talat Bessissow, MD PhD
Claim this profileMcGill University Health Center
Studies Crohn's Disease
Studies Inflammatory Bowel Disease
11 reported clinical trials
16 drugs studied
Affiliated Hospitals
Clinical Trials Talat Bessissow, MD PhD is currently running
TAK-279
for Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
Recruiting0 awards Phase 21 criteria
Colonoscopy Screening
for Colorectal Cancer Risk in IBD
We will conduct a multicenter, parallel-group, non-inferiority RCT in persons with IBD undergoing colorectal neoplasia screening with high-definition white light colonoscopy, comparing a strategy of sampling visible lesions alone to a conventional strategy of sampling both visible lesions as well as normal-appearing mucosa using non-targeted biopsies. The primary outcome is the neoplasia detection rate. The required sample size to demonstrate non-inferiority is 1952 persons.
Recruiting1 award N/A1 criteria
More about Talat Bessissow, MD PhD
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Talat Bessissow, MD PhD has experience with
- TAK-279
- Vedolizumab
- 5-ASA Withdrawal
- Placebo
- Cx601
- Control Group
Breakdown of trials Talat Bessissow, MD PhD has run
Crohn's Disease
Inflammatory Bowel Disease
Colitis
Ulcerative Colitis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Talat Bessissow, MD PhD specialize in?
Talat Bessissow, MD PhD focuses on Crohn's Disease and Inflammatory Bowel Disease. In particular, much of their work with Crohn's Disease has involved treating patients, or patients who are undergoing treatment.
Is Talat Bessissow, MD PhD currently recruiting for clinical trials?
Yes, Talat Bessissow, MD PhD is currently recruiting for 6 clinical trials in Montréal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Talat Bessissow, MD PhD has studied deeply?
Yes, Talat Bessissow, MD PhD has studied treatments such as TAK-279, Vedolizumab, 5-ASA Withdrawal.
What is the best way to schedule an appointment with Talat Bessissow, MD PhD?
Apply for one of the trials that Talat Bessissow, MD PhD is conducting.
What is the office address of Talat Bessissow, MD PhD?
The office of Talat Bessissow, MD PhD is located at: McGill University Health Center, Montréal, Quebec H3G1A4 Canada. This is the address for their practice at the McGill University Health Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.